Главная
Study mode:
on
1
Intro
2
Overview
3
Laboratory-confirmed cryptococcosis in SA GERMS
4
Burden of cryptococcal meningitis (Gauteng Province)
5
Case fatality rate: South Africa
6
CrAg Lateral Flow Assay
7
Implementation and challenges
8
ORCAS trial
9
Open label RCT in Vietnam (n = 299)
10
WHO Guidelines 2011
11
Case scenario
12
IRIS meta-analysis
13
Trials of ART timing in cryptococcal meningitis prior to the COAT trial
14
Randomized Strategy Trial Cryptococcal Optimal ART Timing (COAT) Trial Uganda and South Africa
15
COAT Trial Treatment for Cryptococcal Meningitis
16
Causes of death
17
Early ART initiation particularly harmful if
18
What was cause of excess mortality with early ART in COAT/Zimbabwe trial?
19
Day 14 CSF findings
20
Conclusions (1)
21
Conclusions (2)
22
Acknowledgements
Description:
Explore an in-depth update on cryptococcal disease in HIV-infected patients presented by Graeme Meintjes from the University of Cape Town. Delve into the burden of cryptococcal meningitis in South Africa, examining laboratory-confirmed cases and case fatality rates. Learn about the CrAg Lateral Flow Assay and its implementation challenges. Analyze the ORCAS trial and WHO Guidelines from 2011. Investigate the COAT trial, which studied optimal ART timing in cryptococcal meningitis patients. Examine causes of death and the potential risks of early ART initiation. Gain insights into CSF findings and draw important conclusions about managing cryptococcal disease in HIV patients.

Update on Cryptococcal Disease in HIV-Infected Patients - Lecture 7

Harvard University
Add to list
0:00 / 0:00